R&D | December 12, 2025
OTR Therapeutics and Zealand Pharma join forces to target metabolic diseases
The companies aim to expand treatment options for millions living with metabolic disorders
The companies aim to expand treatment options for millions living with metabolic disorders
The results come from post-hoc analyses of more than 1,500 women enrolled in the Phase 3 ATTAIN-1 and ATTAIN-2 trials, presented at the American Diabetes Association’s 86th Scientific Sessions
The conference highlighted research suggesting that deuterium levels may influence key biological processes
The company is set to unveil new clinical data across obesity, diabetes, kidney, and liver disease programs
POSEIDON is among the largest global datasets to quantify this residual inflammatory burden
Clears major obesity endpoints at 80 weeks
The next-generation proteomics platform powered by Olink™ Explore HT enables simultaneous analysis of thousands of proteins from a single sample
The investment will upgrade and expand production capabilities at Lilly Lebanon API and Lilly Lebanon Advanced Therapies
The study evaluated oral semaglutide in young patients with type 2 diabetes and found it delivered a superior reduction in HbA1c
American College of Cardiology and Korean Society of Cardiology convene global experts to address rising cardiometabolic burden
Subscribe To Our Newsletter & Stay Updated
